Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Report and Forecast 2024-2032

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook

The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% over the forecast period of 2024-2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Targeted therapy for small molecules uses PI3K inhibitors that are relatively new in the area of oncology treatment. The development in the field of targeted therapy and their approvals are driving the growth of the industry globally. The governments across the nations have taken various measures to cut down the cost of these drugs to help patients. Such programmes help patients receive treatment at an affordable price. Thus, the emergence of such reimbursement schemes is one of the key market developments that will fuel the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Market Segmentation

A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a therapeutic drug class that works by inhibiting one or more of the 3-kinase phosphoinositide enzymes.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The global phosphoinositide 3-kinase (PI3K) inhibitors industry can be broadly categorised based on its applications and regions.

• Application
  • CLL - Chronic Lymphocytic Leukaemia
  • FL - Follicular Lymphoma
  • Others

The EMR report looks into the regional phosphoinositide 3-kinase (PI3K) inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

The rising prevalence of cancer around the globe has resulted in the increased demand for chemotherapy and other treatment procedures. Chemotherapy drugs play a significant role in treating cancer. Their drawbacks, however, have produced a change from conventional chemotherapy to targeted therapies. As a result, extensive ongoing research is being performed on targeted therapies such as PI3K inhibitors with demonstrated effectiveness in oncology applications. Significant R&D has contributed to tailored treatments in the dominant therapeutic category. Thus, the recent launches and approvals of targeted therapy during the forecast period will contribute to the growth of phosphoinositide 3-kinase (PI3K) inhibitors industry globally. Although the complex manufacturing process of such drugs makes them expensive, which is becoming a significant challenge for manufacturers and may hamper the industry growth over the forecast period.

Competitive Landscape

The report presents a detailed analysis of the following key players in the global phosphoinositide 3-kinase (PI3K) inhibitors market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Bayer AG
• Gilead Sciences Inc.
• Novartis AG
• TG Therapeutics Inc.
• Verastem Inc.
• Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report